Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT₃ receptor antagonists.

Percie du Sert N, Rudd JA, Apfel CC, Andrews PL.

Cancer Chemother Pharmacol. 2011 Mar;67(3):667-86. doi: 10.1007/s00280-010-1339-4. Epub 2010 May 28. Review.

2.

Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret.

Warneck JB, Cheng FH, Barnes MJ, Mills JS, Montana JG, Naylor RJ, Ngan MP, Wai MK, Daiss JO, Tacke R, Rudd JA.

Toxicol Appl Pharmacol. 2008 Nov 1;232(3):369-75. doi: 10.1016/j.taap.2008.07.003. Epub 2008 Jul 15.

PMID:
18675289
3.

The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret.

Singh L, Field MJ, Hughes J, Kuo BS, Suman-Chauhan N, Tuladhar BR, Wright DS, Naylor RJ.

Eur J Pharmacol. 1997 Feb 26;321(2):209-16.

PMID:
9063690
4.

5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.

Ossi M, Anderson E, Freeman A.

Oncology. 1996 Jun;53 Suppl 1:78-85.

PMID:
8692556
6.

A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.

Sorbe BG, Berglind AM, Andersson H, Boman K, Högberg T, Hallgren M, Schmidt M.

Cancer. 1998 Sep 1;83(5):1022-32.

PMID:
9731907
7.

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH, Borms M, Verbeke L, Van Aelst F, De Smet M, Carides AD, Eldridge K, Gertz BJ.

Eur J Cancer. 2001 May;37(7):835-42.

PMID:
11313170
8.

[Effectiveness of anti-emetics for the prophylaxis of cisplatin-induced delayed emesis: a systematic review].

Kubota Y, Mihara K, Ishii F, Ohno K, Ogata H, Makimura M, Kikuchi N, Kitano T.

Yakugaku Zasshi. 2004 Jan;124(1):1-11. Review. Japanese.

9.
10.

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ.

Cancer. 2002 Jun 1;94(11):3032-41.

11.

Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.

Celio L, Agustoni F, Testa I, Dotti K, de Braud F.

Tumori. 2012 May-Jun;98(3):279-86. doi: 10.1700/1125.12393. Review.

12.

The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.

Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, Slusher BS.

J Pharmacol Exp Ther. 2010 Nov;335(2):362-8. doi: 10.1124/jpet.110.166181. Epub 2010 Aug 19.

13.

Drug treatment of chemotherapy-induced delayed emesis.

Tavorath R, Hesketh PJ.

Drugs. 1996 Nov;52(5):639-48. Review.

PMID:
9118814
14.

Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).

Hesketh PJ, Warr DG, Street JC, Carides AD.

Support Care Cancer. 2011 Sep;19(9):1297-302. doi: 10.1007/s00520-010-0944-4. Epub 2010 Jul 11.

PMID:
20623144
15.

Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting.

Rojas C, Slusher BS.

Eur J Pharmacol. 2012 Jun 5;684(1-3):1-7. doi: 10.1016/j.ejphar.2012.01.046. Epub 2012 Mar 9. Review.

PMID:
22425650
16.

Mechanisms by which cancer chemotherapeutic drugs induce emesis.

Cubeddu LX.

Semin Oncol. 1992 Dec;19(6 Suppl 15):2-13. Review.

PMID:
1485177
17.

Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.

Voravud N, Sriuranpong V.

J Med Assoc Thai. 2005 Dec;88(12):1790-6.

PMID:
16518975
18.

Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.

Pectasides D, Mylonakis A, Varthalitis J, Kostopoulou M, Constantinou A, Papazachariou K, Antoniou F, Dimitriadis M, Athanassiou A.

Oncology. 1997 Jan-Feb;54(1):1-6.

PMID:
8978584
19.

Antiemetic effect of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin-induced acute and delayed emesis in ferrets.

Furukawa TY, Nakayama H, Imazumi K, Yamakuni H, Takeshita K, Matsuo M, Manda T, Uchida W.

Biol Pharm Bull. 2014;37(2):232-8.

20.

[Recent improvements in antiemetic therapy].

Roila F, Palladino MA, Ciccarese G, Basurto C.

Tumori. 1997;83(2 Suppl):S3-14. Review. Italian.

PMID:
9235727

Supplemental Content

Support Center